{"id":60415,"date":"2026-05-05T15:21:36","date_gmt":"2026-05-05T15:21:36","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/60415\/"},"modified":"2026-05-05T15:21:36","modified_gmt":"2026-05-05T15:21:36","slug":"swiss-biotech-report-robust-performance-in-2025","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/60415\/","title":{"rendered":"Swiss biotech report: Robust performance in 2025"},"content":{"rendered":"

\"Michael<\/a>Michael Altorfer, Swiss Biotech Association (l.) and Frederik Schmachtenberg, EY (c) Swiss Biotech Association<\/p>\n

Bildnachweis: Swiss Biotech Association<\/a>.<\/p>\n

Switzerland\u2019s biotech sector delivered a robust performance in 2025, underlining its resilience in a challenging global environment. According to the Swiss Biotech Report 2026<\/a>, unveiled at the Swiss Biotech Day 2026 in Basel by the Swiss Biotech Association in collaboration with EY and six partner organizations, the industry combined record revenues with strong investment momentum. The report\u2019s theme, \u201ctalent and tenacity,\u201d reflects Switzerland\u2019s ability to attract highly skilled professionals while fostering international partnerships.<\/p>\n

Total revenues climbed to an all-time high of CHF 7.5 billion, driven by an increasing number of companies transitioning \u0564\u0565\u057a\u056b the commercial stage and sustained demand for specialized CDMO services. The broader chemical, pharmaceutical and life sciences sectors accounted for 53% of Swiss exports, with immunologicals\u2014including therapeutic proteins, cell therapies and vaccines\u2014reaching a record 20% share. Investment activity also accelerated. Total funding rose to CHF 2.6 billion, with privately held biotech companies securing CHF 1.15 billion\u2014up 38% year-on-year\u2014and representing 45% of total capital inflows. Michael Altorfer, CEO of the Swiss Biotech Association, commented: \u201eThe strong performance of the industry in 2025 is welcome testimony to our commitment to nurturing talent, fostering innovation and promoting international collaboration. Most investment continues to come from abroad and, in USD, has been growing 20 percent compared to the previous year \u2014 an impressive achievement in the current economic and political climate.\u201c<\/p>\n

Growing importance of private capital<\/p>\n

This shift highlights the growing importance of private capital, supported by Switzerland\u2019s internationally oriented collaboration model. Employment in Swiss R&D biotech companies increased to more than 21,000 full-time equivalents, marking another record.\u00a0Frederik Schmachtenberg, Partner at EY, said: \u201eDespite a challenging overall capital markets environment, Swiss biotech companies reported record revenues of CHF 7.5 billion and maintained high R&D investment levels. Total funding reached CHF 2.6 billion, with a shift from public to private companies. Privately funded companies raised a record CHF 1.15 billion, up 38 percent from 2024, and increased their share to 45 percent of total funding, underscoring the strength of the private investor base.\u201c<\/p>\n

Private rounds: central role in 2025<\/p>\n

A closer look at financing trends shows that private rounds played a central role in 2025, with notable raises by Windward Bio (CHF 186 million), GlycoEra (CHF 104 million), Orbis Medicine (CHF 84 million), Nucidium (CHF 79 million) and Rhygaze (CHF 78 million). On the public side, capital markets remained selective, although BioVersys completed Europe\u2019s largest IPO of the year, raising USD 88 million. Follow-on financings were led by Moonlake (CHF 490 million), Oculis (CHF 274 million), Idorsia (CHF 216 million) and ADC Therapeutics (CHF 129 million).\u00a0Strategic transactions and partnerships also gained momentum. CDR-Life entered a global licensing agreement with Boehringer Ingelheim worth up to USD 456 million, BioVersys signed a global research and license option agreement with Shionogi valued at up to CHF 479 million plus royalties, and Windward Bio partnered with Qyuns Therapeutics in a deal worth up to USD 700 million.\u00a0Beyond financing, the report emphasizes the critical role of Switzerland\u2019s talent base in sustaining innovation and global competitiveness. This theme was echoed at the Swiss Biotech Day 2026, which attracted more than 3,500 industry leaders and continues to expand its international footprint through initiatives such as the Global Village.<\/p>\n

Swiss Biotech Success Stories Award<\/p>\n

In recognition of outstanding contributions to the sector, the Swiss Biotech Success Stories Award 2026 was presented to Patrick Aebischer. The renowned neuroscientist and entrepreneur has played a pivotal role in shaping Switzerland\u2019s biotech landscape, including transforming EPFL into a globally leading research institution and founding several biotech companies.<\/p>\n","protected":false},"excerpt":{"rendered":"Michael Altorfer, Swiss Biotech Association (l.) and Frederik Schmachtenberg, EY (c) Swiss Biotech Association Bildnachweis: Swiss Biotech Association.…\n","protected":false},"author":2,"featured_media":60416,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[1831,5032,41,3850,33459,17],"class_list":{"0":"post-60415","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-switzerland","8":"tag-life-sciences","9":"tag-report","10":"tag-swiss","11":"tag-swiss-biotech","12":"tag-swiss-biotech-report","13":"tag-switzerland"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116522653213979698","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/60415","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=60415"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/60415\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/60416"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=60415"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=60415"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=60415"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}